StemMed

StemMed operates as a pre-clinical contract research organization (CRO) specializing in oncology, with a core technology platform centered on a diverse library of patient-derived xenograft (PDX) models. Its services include custom-designed in vivo drug testing, ranging from dose-response studies to large-scale animal trials, primarily for breast and pancreatic cancers. The company is privately held, led by academic founders with deep expertise in cancer biology and STAT3 signaling, and appears to be in an early-revenue stage, monetizing its proprietary PDX models and testing services. Its strategic position leverages the critical need for more predictive pre-clinical models in oncology drug development.

Proprietary library of patient-derived xenograft (PDX) models for breast and pancreatic cancers, developed from an ethnically diverse patient population and representing all major subtypes. Platform is supported by in vivo testing, stem cell assays, and immunostaining services.

StemMed competes within the pre-clinical CRO segment, facing competition from large, full-service CROs (e.g., Charles River, Labcorp) and specialized oncology model providers. Its key differentiators are its focused, ethnically diverse PDX collections and integrated stem cell assay capabilities. It must also contend with evolving competitive technologies like organoids and humanized mouse models.